XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.0.1
Restructuring
 3 Months Ended
Dec. 25, 2021
Restructuring Costs [Abstract]  
Restructuring and Related Activities Disclosure (6) RestructuringDuring the first quarter of fiscal 2022, the Company finalized its decision to close its Danbury, Connecticut facility where it manufactures its Breast Health capital equipment products. The manufacturing of the Breast Health capital equipment products and all other support services will be moved to the Company's Newark, Delaware facility. In addition, research and development, sales and services support and administrative functions will be moved to the Newark and Marlborough, Massachusetts facilities as well. The transition is expected to be completed by the third quarter of fiscal 2025. The majority of employees located in Danbury have been given the option to relocate to the new locations and have until the end of March 2022 to make a decision. As a result of this plan, the Company expects a number of employees to not relocate resulting in their termination. The employees were notified of the closure in the three months ended December 25, 2021, but were not communicated their termination or severance and related benefits. As such, no severance and benefits charges were recorded in the first quarter of fiscal 2022 pursuant to ASC 420, Exit or Disposal Cost Obligations (ASC 420). The Company estimates that total severance and benefits charges, including retention, will be approximately $13.0 million and will be recorded ratably over the performance period once the communication date is met.